Nxera and AbbVie Sign $1.47B IBD Drug Licensing Deal
Tokyo, Japan, and Cambridge, United Kingdom, November 4, 2026 Nxera Pharma Co., Ltd. has entered into an exclusive global...
IBD
Advertisement
XtalPi Advances KQTD-126 Into FDA IND Review
Boston, Massachusetts, and Shenzhen, China, September 24, 2026 XtalPi has reached a significant milestone in its proprietary drug-development pipeline...
Palisade Bio Gains FDA IND Clearance for PALI-2108
DENVER, Colo. — September 22, 2026 Palisade Bio announced that the U.S. Food and Drug Administration has cleared the...
HFSA Highlights Late-Breaking Heart Failure Clinical Research
Washington, D.C., September 20, 2026 The Heart Failure Society of America (HFSA) has announced the late-breaking clinical research program...
Accro Bioscience Advances AC-101 in Ulcerative Colitis
New York, United States, September 20, 2026 Accro Bioscience has announced that the first patient has been dosed in...
Advertisements
Spyre Therapeutics Advances SPY003 in UC with Positive Phase 2 Data
WALTHAM, Mass. — September 8, 2026 Spyre Therapeutics announced positive 12-week induction results from Part A of the Phase...
Greywolf Therapeutics Advances GRWD0715 Into axSpA Trial
LONDON — September 8, 2026 Greywolf Therapeutics announced that it has dosed the first participants with axial spondyloarthritis (axSpA)...
Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Palisade Bio Advances PALI-2108 Into Phase 2 IBD Trials
DENVER, Colorado, August 10, 2026 Palisade Bio, Inc. announced its second-quarter 2026 financial results and provided a business update...
Fresenius Kabi’s Vedolizumab Biosimilar Accepted for FDA and EMA Review
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
Advertisement
